Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
UHS vs DBVT vs HCA vs ALKS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Care Facilities
Biotechnology
Medical - Distribution
UHS vs DBVT vs HCA vs ALKS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Medical - Care Facilities | Biotechnology | Medical - Distribution |
| Market Cap | $10.68B | $1712.35T | $95.95B | $5.90B | $92.15B |
| Revenue (TTM) | $17.76B | $0.00 | $75.60B | $1.56B | $403.43B |
| Net Income (TTM) | $1.52B | $-168M | $6.78B | $153M | $4.76B |
| Gross Margin | 67.6% | — | 41.5% | 65.4% | 3.6% |
| Operating Margin | 11.5% | — | 15.8% | 12.3% | 1.5% |
| Forward P/E | 7.3x | — | 14.2x | 24.8x | 19.3x |
| Total Debt | $5.51B | $22M | $50.20B | $70M | $7.39B |
| Cash & Equiv. | $138M | $194M | $1.04B | $1.12B | $5.69B |
UHS vs DBVT vs HCA vs ALKS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Universal Health Se… (UHS) | 100 | 161.7 | +61.7% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| McKesson Corporation (MCK) | 100 | 474.1 | +374.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UHS vs DBVT vs HCA vs ALKS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
UHS ranks third and is worth considering specifically for valuation efficiency.
- PEG 0.46 vs HCA's 0.67
- Lower P/E (7.3x vs 19.3x), PEG 0.46 vs 0.49
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs UHS's -8.2%
HCA has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- 450.5% 10Y total return vs MCK's 348.1%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- 0.7% yield, 5-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs DBVT's 0.3%
MCK is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 16.2% revenue growth vs DBVT's -100.0%
- Beta 0.04 vs DBVT's 1.26
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (7.3x vs 19.3x), PEG 0.46 vs 0.49 | |
| Quality / Margins | 9.8% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.04 vs DBVT's 1.26 | |
| Dividends | 0.7% yield, 5-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs UHS's -8.2% | |
| Efficiency (ROA) | 11.3% ROA vs DBVT's -89.0% |
UHS vs DBVT vs HCA vs ALKS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
UHS vs DBVT vs HCA vs ALKS vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MCK leads in 2 of 6 categories
ALKS leads 1 • UHS leads 1 • DBVT leads 0 • HCA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK and DBVT operate at a comparable scale, with $403.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to MCK's 1.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $17.8B | $0 | $75.6B | $1.6B | $403.4B |
| EBITDAEarnings before interest/tax | $2.7B | -$112M | $15.5B | $212M | $6.8B |
| Net IncomeAfter-tax profit | $1.5B | -$168M | $6.8B | $153M | $4.8B |
| Free Cash FlowCash after capex | $894M | -$151M | $7.7B | $392M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +67.6% | — | +41.5% | +65.4% | +3.6% |
| Operating MarginEBIT ÷ Revenue | +11.5% | — | +15.8% | +12.3% | +1.5% |
| Net MarginNet income ÷ Revenue | +8.6% | — | +9.0% | +9.8% | +1.2% |
| FCF MarginFCF ÷ Revenue | +5.0% | — | +10.2% | +25.1% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.6% | — | +6.7% | +28.2% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.7% | +91.5% | +44.6% | -4.1% | +37.0% |
Valuation Metrics
UHS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 7.4x trailing earnings, UHS trades at a 75% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), UHS offers better value at 0.46x vs MCK's 0.75x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $10.7B | $1712.35T | $95.9B | $5.9B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $16.0B | $1712.35T | $145.1B | $4.9B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | 7.38x | -0.76x | 15.12x | 24.76x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.30x | — | 14.19x | — | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | 0.46x | — | 0.72x | — | 0.75x |
| EV / EBITDAEnterprise value multiple | 6.14x | — | 9.37x | 17.25x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 0.61x | — | 1.27x | 4.00x | 0.26x |
| Price / BookPrice ÷ Book value/share | 1.48x | 0.66x | — | 3.28x | — |
| Price / FCFMarket cap ÷ FCF | 12.57x | — | 12.47x | 12.28x | 17.63x |
Profitability & Efficiency
MCK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to UHS's 0.74x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +20.7% | -130.2% | — | +8.8% | +3.0% |
| ROA (TTM)Return on assets | +9.8% | -89.0% | +11.3% | +5.4% | +5.7% |
| ROICReturn on invested capital | +12.3% | — | +19.9% | +18.9% | +5.4% |
| ROCEReturn on capital employed | +16.0% | -145.7% | +27.0% | +14.2% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.74x | 0.13x | — | 0.04x | — |
| Net DebtTotal debt minus cash | $5.4B | -$172M | $49.2B | -$1.0B | $1.7B |
| Cash & Equiv.Liquid assets | $138M | $194M | $1.0B | $1.1B | $5.7B |
| Total DebtShort + long-term debt | $5.5B | $22M | $50.2B | $70M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | 10.92x | -189.82x | 5.37x | 32.30x | 33.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs UHS's -8.2%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs ALKS's 4.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -22.3% | +4.9% | -8.6% | +25.3% | -8.5% |
| 1-Year ReturnPast 12 months | -8.2% | +110.4% | +19.7% | +16.5% | +4.6% |
| 3-Year ReturnCumulative with dividends | +20.8% | +19.7% | +57.4% | +14.5% | +106.4% |
| 5-Year ReturnCumulative with dividends | +12.5% | -69.1% | +109.7% | +60.9% | +286.9% |
| 10-Year ReturnCumulative with dividends | +30.8% | -87.0% | +450.5% | -11.0% | +348.1% |
| CAGR (3Y)Annualised 3-year return | +6.5% | +6.2% | +16.3% | +4.6% | +27.3% |
Risk & Volatility
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs UHS's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.60x | 1.26x | 0.29x | 1.06x | 0.04x |
| 52-Week HighHighest price in past year | $246.33 | $26.18 | $556.52 | $36.60 | $999.00 |
| 52-Week LowLowest price in past year | $152.33 | $7.53 | $330.00 | $25.17 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +69.2% | +76.3% | +77.1% | +96.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 39.7 | 48.1 | 30.8 | 60.2 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 793K | 252K | 1000K | 2.3M | 757K |
Analyst Outlook
Evenly matched — HCA and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: UHS as "Hold", DBVT as "Buy", HCA as "Buy", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.9% for HCA (target: $527). For income investors, HCA offers the higher dividend yield at 0.69% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $231.50 | $46.33 | $527.45 | $44.00 | $1006.50 |
| # AnalystsCovering analysts | 43 | 15 | 46 | 28 | 31 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | — | +0.7% | — | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 5 | 0 | 17 |
| Dividend / ShareAnnual DPS | $0.80 | — | $2.94 | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +9.1% | 0.0% | +10.5% | +0.5% | +3.4% |
MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.
UHS vs DBVT vs HCA vs ALKS vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is UHS or DBVT or HCA or ALKS or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UHS or DBVT or HCA or ALKS or MCK?
On trailing P/E, Universal Health Services, Inc.
(UHS) is the cheapest at 7. 4x versus McKesson Corporation at 29. 2x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Universal Health Services, Inc. wins at 0. 46x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — UHS or DBVT or HCA or ALKS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HCA returned +450. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UHS or DBVT or HCA or ALKS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2818% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 74% for Universal Health Services, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — UHS or DBVT or HCA or ALKS or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Universal Health Services, Inc. grew EPS 37. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — UHS or DBVT or HCA or ALKS or MCK?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is UHS or DBVT or HCA or ALKS or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Universal Health Services, Inc. (UHS) is the more undervalued stock at a PEG of 0. 46x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 19. 3x for McKesson Corporation — 12. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — UHS or DBVT or HCA or ALKS or MCK?
In this comparison, HCA (0.
7% yield), UHS (0. 5% yield), MCK (0. 4% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is UHS or DBVT or HCA or ALKS or MCK better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between UHS and DBVT and HCA and ALKS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: UHS is a mid-cap deep-value stock; DBVT is a mega-cap quality compounder stock; HCA is a mid-cap deep-value stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. HCA pays a dividend while UHS, DBVT, ALKS, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.